IVF Live Birth Rates at 35, 38, and 41: Cumulative Success Math Across 2–3 Cycles — and How AI Prior Auth Denials and a $30K Clinic Cost Gap Should Drive Your 2026 Decision
The question nobody asks before their first IVF cycle: What is my cumulative probability of live birth across two or three cycles, and what will that actually cost me total?
You get quoted $12,000–$15,000 for a cycle. You hear a stat — "our success rate is 55%!" — and you think: okay, decent odds. But that single-cycle number is almost never the right metric. Most patients who ultimately achieve a live birth do so after more than one retrieval. And when the true per-cycle cost runs $25,000–$36,000 once medications, monitoring, PGT, and an FET are factored in, the math across two or three cycles changes everything about which clinic you choose and how you budget for this.
Here's what the data actually shows — and why 2026 has introduced two new variables that can blow up even a carefully built financial plan.
What SART Data Actually Shows for Your Age Group
Feralyx's analysis of the CDC ART reporting dataset — 2,880 rows of clinic-level IVF outcomes drawn from the cdc_art_ivf_success_rates source — produces the following per-retrieval-cycle live birth rates by age bracket. These are national averages across SART-reporting clinics, not the cherry-picked numbers on any clinic's homepage.
| Age Group | Per-Cycle Live Birth Rate (national avg) | Clinic Range (low–high) |
|---|---|---|
| Under 35 | ~47% | 38%–62% |
| 35–37 | ~37% | 28%–52% |
| 38–40 | ~26% | 17%–41% |
| 41–42 | ~16% | 8%–28% |
| 43+ | ~6% | 2%–14% |
That clinic range column is doing enormous work. The gap between the lowest and highest performer is 20+ percentage points at every age bracket. For a 40-year-old, that's the difference between a 17% and a 41% per-cycle probability — and that gap compounds dramatically when you're planning for multiple attempts.
For a deeper look at how to decode SART reports for your specific age and diagnosis, this breakdown on reading IVF live birth rates by age and clinic walks through exactly what those outcome tables are actually measuring — and what high-performing clinics routinely obscure.
The Cumulative Success Math Nobody Shows You
Here's the calculation that should anchor every treatment planning conversation. Cumulative probability of live birth across N independent cycles follows a straightforward formula:
P(success across N cycles) = 1 - (1 - p)^N
where p is the per-cycle live birth rate at your age.
Using Feralyx's cdc_art_ivf_success_rates dataset, here's what cumulative success looks like at three clinically important age points:
| Age | Per-Cycle Rate | After 1 Cycle | After 2 Cycles | After 3 Cycles |
|---|---|---|---|---|
| 35 | 47% | 47% | 71.9% | 85.1% |
| 38 | 26% | 26% | 45.2% | 59.5% |
| 41 | 16% | 16% | 29.4% | 40.7% |
This is the math that changes your clinic decision.
A 35-year-old has an 85% cumulative probability of live birth after three cycles — but achieves live birth within two cycles 72% of the time. A 41-year-old doing three cycles has a 40.7% cumulative probability at the national average clinic.
But at a high-performing clinic where the per-cycle rate is 28% instead of 16%, that same person's three-cycle cumulative probability becomes:
1 - (0.72)^3 = 1 - 0.373 = 62.7% cumulative probability
That's a 22-point swing in cumulative live birth probability — from the same three attempts — based entirely on clinic selection. No change in protocol. No change in diagnosis. Just which clinic you walked into.
What Cumulative Success Actually Costs You
Success rates only matter in the context of what you're paying to access them. Here's the honest math, drawn from Feralyx's ivf_costs dataset (600 rows of real clinic pricing data) and medication_costs dataset (240 rows of current pharmacy pricing):
| Cost Component | Low End | High End |
|---|---|---|
| Clinic base fee | $12,000 | $15,000 |
| Injectable medications (stims) | $4,000 | $7,000 |
| PGT-A genetic testing | $3,000 | $6,000 |
| Monitoring (if billed separately) | $1,500 | $3,000 |
| FET (if retrieval fee excludes it) | $3,000 | $5,000 |
| Realistic per-cycle total | $23,500 | $36,000 |
The mid-range lands at $28,000–$30,000 — a figure consistent with Feralyx's full IVF cost breakdown for 2026. Now multiply across the cycles most patients actually need:
| Age | Cycles to Reach ~60% Cumulative Probability | Total Cost Range |
|---|---|---|
| 35 | 2 cycles (~72%) | $47,000–$72,000 |
| 38 | 3 cycles (~60%) | $70,500–$108,000 |
| 41 | 3 cycles at avg clinic (~41%); need top-quartile clinic to approach 60% | $70,500–$108,000 |
This is where the clinic comparison stops being academic. For a 41-year-old, choosing a clinic with a 28% per-cycle rate instead of the national average 16% doesn't just improve probability — it may eliminate an entire cycle ($28,000–$36,000) from the financial plan, because you reach a meaningful cumulative threshold with fewer attempts.
This is the kind of modeling Feralyx runs for your specific age, diagnosis, and clinic shortlist — because building this comparison from scratch requires pulling across 2,880 rows of CDC outcomes data and 600 rows of real cost data simultaneously.
The 2026 Variable Nobody Planned For: AI Prior Authorization
A KFF Health News investigation published this week documented how major health insurers — and even Medicare — are deploying artificial intelligence systems to make coverage decisions at scale. Class action lawsuits have accused these insurers of using AI to wrongfully deny treatment, and new research confirms the risks are substantial and growing.
For fertility patients, this creates a specific and expensive problem.
Prior authorization already delays or blocks coverage for injectable medications, monitoring cycles, and certain retrieval procedures. When that review process is handed to an AI model trained to flag high-cost claims, denial rates climb — and the appeal process can add weeks of delay to a time-sensitive cycle protocol. Missing a stimulation window at age 40 or 41 isn't just frustrating; it carries real clinical consequences given how rapidly ovarian reserve declines with age.
What this means financially: If your plan covers any portion of fertility treatment and you're in a mandate state, an AI-driven prior auth denial can shift $4,000–$10,000 from covered to out-of-pocket in a single cycle. Feralyx's state_fertility_mandates dataset (51 rows covering all states plus D.C.) shows that even in states with IVF coverage mandates, plan-level gaps are pervasive — and AI denial systems are making those gaps wider and harder to predict in advance.
For a full picture of how insurance mandates, ERISA carve-outs, and prior auth interact with your actual coverage situation, this 2026 IVF insurance coverage breakdown covers exactly what patients with and without employer-sponsored plans should know before their next retrieval cycle.
The HHS Budget Wildcard and What It Means for SART Data
Julie Rovner's KFF Health News reporting this week also addressed the Trump administration's proposed HHS budget, which includes deep cuts to Health and Human Services infrastructure. Meanwhile, ongoing proposals around Medicaid restructuring are creating downstream pressure on hospital systems that house fertility clinics — particularly safety-net providers that serve lower-income patients.
Here's the less-discussed risk: SART's outcome data exists because of CDC ART reporting requirements. If HHS budget cuts reduce CDC's capacity to collect, process, and publish annual ART outcomes reports, patients lose their primary independent benchmarking tool for clinic comparison. You'd be left with only what clinics choose to self-report on their own websites — which is systematically incomplete.
Feralyx's cdc_art_ivf_success_rates dataset (2,880 rows) and cdc_art_diagnosis_success_rates dataset (360 rows) represent a current snapshot of this publicly available data. The long-term risk is real: if CDC reporting becomes less comprehensive or less timely, the ability to compare clinics on independent outcome data gets materially harder.
This makes the current window — while independent, clinic-level outcome data is still accessible and comparable — a critical time to do this analysis before committing to a clinic and a treatment plan.
The Three Numbers You Need From Every Clinic Before Your Next Cycle
Before signing any agreements, get these three data points from every clinic you're evaluating:
-
Live birth rate per retrieval cycle for your age bracket — not per transfer, not per egg retrieved. Per retrieval, which includes canceled cycles, failed fertilizations, and failed transfers in the denominator.
-
Cycle cancellation rate — the percentage of patients who start stimulation but have their retrieval canceled before egg collection. A high cancellation rate is how low-performing clinics hide poor responders and inflate their published success statistics.
-
All-in cost per cycle — base clinic fee plus medications, monitoring, PGT-A, and FET. Not the quote. The all-in number.
Then run the cumulative math yourself. Consider this worked comparison for a 40-year-old patient:
Clinic A: $32,000 all-in per cycle, 30% per-cycle live birth rate
- 2-cycle cumulative: 1 - (0.70)^2 = 51%
- 2-cycle total cost: $64,000
Clinic B: $26,000 all-in per cycle, 22% per-cycle live birth rate
- 2-cycle cumulative: 1 - (0.78)^2 = 39.2%
- 3-cycle total to approach similar odds: $78,000 — and still 12 points lower
The cheaper clinic costs $14,000 more over the treatment journey and delivers worse cumulative odds. The sticker price comparison almost always points patients toward the wrong decision.
For a full guide to decoding SART cancellation rates and understanding why the $15K–$30K price gap between clinics rarely means what patients assume, this clinic comparison deep dive lays out the full analytical framework.
Before You Commit to Another Cycle
The fertility treatment decision in 2026 carries more variables than ever before: AI prior auth systems quietly shifting costs from covered to out-of-pocket, Medicaid and HHS budget uncertainty threatening the infrastructure patients rely on for independent clinic benchmarking, and clinic-to-clinic variation of 20+ percentage points in success rates that can mean the difference between 41% and 63% cumulative live birth probability across the same three attempts.
Nobody should make this decision from a single clinic's quoted success rate and an incomplete $12,000 base price estimate.
Feralyx pulls together CDC ART outcomes data, clinic-level SART reporting, real medication cost ranges by market, and state insurance mandate coverage into a single analysis — so you can model cumulative probability and true total cost for your specific age, diagnosis, clinic options, and insurance situation before you schedule a consultation or sign a treatment agreement.
The math is complicated. The stakes are high enough that getting it wrong isn't just expensive — it's a cycle you don't get back.
Sources
- Rovner Recaps Medicaid Cuts’ Impact on Hospitals and Fields Caller Questions on Affordability — KFF Reproductive Health
- For Many Patients Leaving the ICU, the Struggle Has Only Just Begun — KFF Reproductive Health
- The Trump Administration Is Seeking Federal Workers’ Sensitive Medical Data. That’s Raising Alarms. — KFF Reproductive Health
- Watch: As AI Makes More Health Coverage Decisions, the Risks to Patients Grow — KFF Reproductive Health
- What the Health? From KFF Health News: Abortion Pills, the Budget, and RFK Jr. — KFF Reproductive Health